MedNous | Business of medical innovation

Evernow Publishing Ltd Privacy Policy. Read more.

Free featured article

MorphoSys readies commercial operations

Country

Germany

MorphoSys AG is further expanding its commercial operations in the US in anticipation of Food and Drug Administration approval of its first wholly-owned antibody therapeutic by the middle of 2020. The product, MOR208, is an Fc-engineered antibody directed against the cancer antigen CD19. It is being developed for diffuse large B cell lymphoma in patients with relapsed disease who are not eligible for high-dose chemotherapy or a stem cell transplant.

TreeFrog Therapeutics secures funding

Country

France

A new French company working in the field of stem cell culture has raised €7.1 million in a Series A financing round to advance its technology for mass producing stem cells. TreeFrog Therapeutics SAS was founded in November 2018 on the basis of years of academic research.

Evotec confirms financial guidance

Country

Germany

Following a first quarter in which revenue increased by 27%, Evotec SE expects its business will grow by 10% this year – confirming earlier forecasts. The march forward reflects continued demand for its drug discovery services as well as ongoing milestone payments from drug development partners such as Bayer AG, Boehringer Ingelheim GmbH and Second Genome Inc.